DHA Supplements Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Preventive Brain, Eye, and Cardiovascular Health Adoption

Evidence from recent clinical research is affecting how companies position DHA supplement products. A 2025 Scientific Reports dose-response meta-analysis covering 58 randomized controlled trials associated omega-3 supplementation at 1,000 mg to 2,500 mg daily with improvements in attention, primary memory, and visuospatial function.^[1] The analysis found that the benefit window was dose-specific rather than linear, which supports more precise formulation and communication choices. A 2025 JACC Advances meta-analysis of 16 trials involving 127,771 patients found a cardiovascular mortality hazard ratio of 0.79 for purified EPA and 0.92 for EPA and DHA combinations.^[2] This distinction separates cardiovascular-oriented EPA propositions from DHA-centered brain and vision products. It also gives manufacturers a clearer basis for matching ingredient ratios to the health need addressed by each DHA supplement market offering.

Prenatal and Infant DHA Fortification

Maternal and infant nutrition is providing a demand base that is less dependent on discretionary wellness spending. The U.S. National Institutes of Health Office of Dietary Supplements issued guidance in 2025 recommending at least 250 mg daily of DHA plus EPA for women of childbearing age and an additional 100 mg to 200 mg of DHA during pregnancy. The World Health Organization and the European Food Safety Authority support a daily DHA intake of 200 mg for pregnant and lactating women. A 2025 Nutrients article reported average DHA and EPA intake near 100 mg per day in high-income countries, showing a substantial intake gap.^[3] DSM-Firmenich offers maternal oils and powders that deliver 350 mg DHA in either a softgel or 2-gummy serving. These formats allow DHA supplements market brands to address the need for high-dose, odor-controlled prenatal products.

Aging and Nutritional-Gap Supplementation

Aging populations are widening the role of DHA beyond conventional cognition claims. The 2025 DO-HEALTH trial reported that omega-3 supplementation slowed biological aging by as much as 3.8 months over 3 years according to DNA methylation clocks. An overview of systematic reviews covering 26,881 people aged 40 years and older found a modest improvement in Mini-Mental State Examination scores among n-3 PUFA supplement users. A separate 2025 review linked long-chain omega-3 fatty acids with a possible role in sarcopenia prevention. These findings give the DHA supplements market a broader healthspan proposition for older consumers. They also support investment in convenient, tolerable formats for people managing several health and nutrition needs.

Vegan and Sustainable Algal DHA Adoption

Algal DHA is becoming a supply and formulation choice, rather than only a vegan alternative. Controlled fermentation can offer consistent DHA quality without seasonal fishery exposure, which is useful for infant formula and premium supplements. Sumitomo Corporation signed an exclusive agreement in January 2025 to distribute Huvepharma algal DHA in Japan. Aker BioMarine expanded the commercial reach of its Revervia algae ingredient during 2025, including an India entry in January 2026. Online subscriptions and personalized product bundles can further help suppliers retain buyers of premium algal formats, while microencapsulation makes DHA easier to place in gummies and chewables. These changes may reduce the DHA supplements market dependence on large softgels and conventional marine oils over time.

Marine Supply Volatility and Quota Exposure

The DHA supplements market remains exposed to concentrated and climate-sensitive marine supply. Peru set its first 2025 anchovy season quota at 3 million metric tons, but the reported 15% EPA and 15% DHA profile did not match the preferred ratios used by many supplement manufacturers. IFFO reported global fish oil production of 1.2 million to 1.3 million tons for 2025. Competing uses in dietary supplements, premium pet nutrition, and aquaculture can redirect available fish oil and raise costs. GOED has encouraged diversification across algae, krill, calanus, sardine, and tuna oil to reduce concentration risk. This exposure can compress margins during a fishery cycle even when finished-product demand remains resilient.

Oxidation, Dose Loading, and Shelf-Life Constraints

DHA is highly unsaturated and therefore vulnerable to oxidation during processing, storage, and distribution. A 2025 review in the Journal of the American Oil Chemists’ Society found that encapsulation can improve DHA bioavailability by 50% to 150% while protecting the ingredient against oxidation. Spray drying, coacervation, and nanoemulsion systems can be costly for smaller manufacturers. The issue is especially relevant in gummies because heat can degrade unprotected oils during manufacturing. DSM-Firmenich stated that its life's OMEGA 033-P100 powder can deliver up to 500 mg omega-3 in a 2-piece gummy while protecting the oil from heat, oxygen, and light. Regulatory claim requirements and the higher price of algal inputs add further pressure on product economics, particularly in price-sensitive markets.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

DHA Supplements Market Segment Analysis

Capsules held 48.13% of DHA supplements market share in 2026, supported by dose precision, physician familiarity, and established molecular-distillation supply chains. Their familiar format remains useful for adults seeking concentrated daily intake. Softgels continue to serve premium users who value enteric delivery and higher omega-3 loading. Ghost Sports Nutrition introduced Basics Fish Oil in March 2025 with 2.4 g of enteric-coated omega-3 per 2-capsule serving using an Epax Norway AS ingredient. This example reflects continued demand for performance and wellness products built around conventional softgel delivery.

Gummies and chewables are projected to grow at a 7.73% CAGR through 2032, the fastest product-format rate in the DHA supplements market. Their growth reflects the need to reduce taste, odor, and swallowing barriers for children, pregnant consumers, and occasional supplement users. Encapsulation makes it possible to increase DHA loading while reducing oxidation risk. Sirio introduced XtraGummies in March 2025 with 125 mg DHA per gummy, illustrating how the format is moving toward clinically relevant doses. Powders and liquids also support flexible dosing in pediatric sachets and maternal nutrition, particularly where clinical dispensing affects purchase choices.

Fish oil held 58.38% of share in the DHA supplements market by source in 2026. Its infrastructure, established consumer awareness, and cost profile retain advantages in mass-market formulations. High-value fish oil producers increasingly compete through concentration, low-oxidation processing, and third-party sustainability credentials. Epax Norway AS, GC Rieber VivoMega, and Golden Omega S.A. represent suppliers that use these attributes to move beyond volume-price competition. This strategy allows fish oil products to remain relevant while buyers place greater emphasis on quality and traceability.

Algal oil is projected to grow at a 9.03% CAGR through 2032, the highest rate among source segments in the DHA supplements market. It benefits from vegan demand, infant-formula use, and controlled fermentation conditions that reduce dependence on seasonal fisheries. Sumitomo Corporation’s Japanese distribution agreement for Huvepharma algal DHA demonstrates a sourcing shift toward fermentation-based supply. Aker BioMarine’s 2025 expansion of its Revervia algae ingredient also shows growing business-to-business interest. Krill oil retains a phospholipid-based absorption proposition, while calanus and other oils remain smaller diversification options.

Adults accounted for 54.24% of share in the DHA supplements market in 2026. This group includes consumers focused on cardiovascular wellness, cognition, vision, sports performance, and healthy aging. Adult demand supports a broad range of price points and formulations. Pregnant and lactating women remain an underpenetrated adult subsegment because intake often falls below recommended levels. This gap gives manufacturers room to develop high-dose products with simpler dosing and better taste control.

Children and infants are projected to grow at an 8.23% CAGR through 2032 in the DHA supplements market. Physician guidance and parental concern about early brain and visual development support this demand. Product acceptance depends on age-appropriate flavor, form, and dose presentation. The 2025 International Society of Sports Nutrition position stand also reported that EPA and DHA can support endurance capacity, adding a clinical reference for active-nutrition communication to adult consumers. The result is a consumer base where life stage shapes both product design and channel choice.

Dietary supplements represented 53.16% of share in the DHA supplements market by application in 2026. The category addresses preventive cardiovascular, cognitive, and eye-health needs across adult populations. Functional foods and beverages are gaining relevance as encapsulation allows DHA to enter dairy alternatives and meal-replacement formats. Pharmaceuticals and clinical nutrition remain smaller but high-value applications. Corbion identified algae-derived omega-3 DHA for pet nutrition and human nutrition as a driver of its 2025 performance. These adjacent applications can support ingredient utilization beyond conventional supplements.

Infant formula and infant nutrition are projected to grow at an 8.73% CAGR through 2032 in the DHA supplements market. Their growth is supported by regulation and clinical guidance rather than consumer preference alone. The European Union requires DHA in infant formula under its compositional rules. The U.S. Food and Drug Administration reviewed infant-formula nutrient requirements, including DHA, through its Operation Stork Speed Expert Panel process in 2025. These requirements create a durable foundation for specialized DHA ingredients.

Pharmacy and drug stores held a 42.03% share in the DHA supplements market in 2026. Pharmacist guidance and physician recommendations remain important for prenatal, geriatric, and clinical DHA uses. The channel also reassures buyers who seek help selecting dose and format. Supermarkets and hypermarkets give private-label products access to high-volume, value-oriented shoppers. Specialty stores remain relevant for algal DHA, krill oil, and pharmaceutical-grade concentrates that require more detailed product explanation.

Online stores and direct-to-consumer channels are projected to grow at an 8.01% CAGR through 2032 in the DHA supplements market. Subscription replenishment and digital product bundles can improve repeat purchase behavior. Practitioner channels combine clinical trust with direct fulfillment. Duly Health and Care partnered with Fullscript in April 2025 to recommend and ship supplements directly to patients. This model shows how clinical channels can extend into direct-to-consumer logistics without losing their advisory role.

Geography Analysis

North America

North America accounted for 39.31% of the share in the DHA supplements market in 2026. High per-capita supplement spending, mature pharmacy networks, and regular clinical recommendations support the region’s established position. In the United States, the American Heart Association recommends 1 g of EPA and DHA daily for secondary prevention in patients with coronary heart disease. The 2025 NIH guidance on omega-3 intake during pregnancy also strengthens the basis for prenatal products. Canada adds ingredient innovation through companies such as Mara Renewables, while Mexico offers room for lower-priced pharmacy products. Product development is increasingly focused on algal oils, maternal formats, and products that meet U.S. dietary-supplement labeling and quality expectations.

Asia-Pacific

Asia-Pacific is projected to grow at a 7.95% CAGR through 2032, the fastest geographic rate in the DHA supplements market. China, India, South Korea, Japan, and Australia are expanding demand through urbanization, online retail, and preventive health spending. In Japan, Sumitomo Corporation’s 2025 agreement and Rohto Pharmaceutical’s 100% algae-derived DHA and EPA supplement launch point to broader acceptance of plant-based omega-3 products. India is building awareness around maternal and pediatric DHA, while Australia has a defined pathway for listed complementary medicines through the Therapeutic Goods Administration. Localized digital communication and convenient child-friendly formats are likely to shape supplier strategies. These conditions make the region important for both volume growth and algal DHA adoption.

Europe, Middle East, Africa, and South America

Europe benefits from an established regulatory influence through authorized European Food Safety Authority health claims for DHA and normal brain function, vision, and cardiac function when intake conditions are met. The DHA supplements market size in Europe is supported by aging populations and a growing vegan consumer base, especially in Germany, France, and the United Kingdom. BTC Europe signed an EU27 distribution agreement with Solutex for the Omegatex range in April 2025, supporting access to fish- and algae-oil ingredients. The Middle East and Africa have higher penetration in Gulf Cooperation Council countries, where halal certification can complement vegan algal positioning. South America is developing retail infrastructure in Brazil and Argentina, while proximity to Peruvian and Chilean fish-oil sources could support future downstream manufacturing. These mixed regions require different pricing, certification, and distribution approaches rather than a single regional proposition.